Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Idelalisib shows long-term safety, efficacy for relapsed CLL

Key clinical point: For patients with relapsed/refractory chronic lymphocytic leukemia, long-term treatment with idelalisib appears safe and effective.

Major finding: Patients who received a combination of rituximab and idelalisib followed by idelalisib monotherapy had a median overall survival of 40.6 months.

Study details: A randomized, double-blind, phase 3 trial involving patients with relapsed/refractory chronic lymphocytic leukemia.

Disclosures: Gilead Sciences funded the study. Dr. Sharman reported financial relationships with Gilead and other companies.


Sharman JP et al. J Clin Oncol. 2019 Apr 17. doi: 10.1200/JCO.18.01460.